Abstracts - faqs.org

Abstracts

News, opinion and commentary

Search abstracts:
Abstracts » News, opinion and commentary

Rules on patient privacy force companies to seek new ways to distribute samples and information

Article Abstract:

Now that the Health Insurance Portability and Accountability Act has taken effect, doctors may no longer share information about patients with marketers. Physicians may ask patients to provide personal information to marketers on an opt-in basis. This method appears to be working, with temporary, minor ailments producing better opt-in results, as consumers seek out free merchandise in the form of marketers' samples and discount coupons.

Author: Bannan, Karen J.
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2003
Public affairs, Ethics, Physician and patient, Physician-patient relations, Ethical aspects, Privacy, Right of, Right of privacy, Medical records, Patients' rights

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


F.D.A. Panel Votes Against Sale of Statins Over Counter

Article Abstract:

While a Food and Drug Administration Advisory Panel voted against recommending the over-the-counter sale of Mevacor, a popular and well-established cholesterol-lowering drug, Merck and Johnson & Johnson plan to keep on trying to win approval.

Author: Saul, Stephanie
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
Alliances, partnerships, Johnson & Johnson, Alliances and partnerships, JNJ, Merck & Company Inc., Statins, Mevacor (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Pfizer to Halt Its Advertising Of Celebrex To Consumers

Article Abstract:

Pharmaceutical company Pfizer Inc. will stop advertising the pain reliever Celebrex. The company already spent over $71 million advertising Celebrex, which has been shown to increase the risk of heart attacks.

Author: Berenson, Alex
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2004
Product standards, safety, & recalls, Product defects and recalls, Complications and side effects, Pfizer Inc., COX-2 inhibitors, PFE, Celebrex (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Laws, regulations and rules, Pharmaceutical industry, Marketing, Government regulation, Advertising, Company marketing practices, United States. Food and Drug Administration
Similar abstracts:
  • Abstracts: RIM stock price slides on court's patent ruling. More cuts seen imminent at Bombardier division. ATI stock surges 22% as results beat forecasts
  • Abstracts: Energy costs spur commodities: Consumers may soon feel pinch of rising agriculture plastics and metal costs
  • Abstracts: Vengold faces criticism for forgiving loans to executives. Telus to enter B.C. TV market. Angiotech considers answers to options dilemma
  • Abstracts: Worn-out middle managers may get protection. Telus union ordered to stop intimidation. Wal-Mart must give union access
  • Abstracts: Holders press MCI to consider Qwest offer. MCI resists lure of cash and picks stability. Buyer found for Ebbers ranch
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.